AI assistant
Sending…
Pulmonx Corp — Director's Dealing 2021
Apr 9, 2021
34428_dirs_2021-04-08_8f5b8fd8-2a0a-4a6f-9ddd-714d9971c833.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: Pulmonx Corp (LUNG)
CIK: 0001127537
Period of Report: 2020-12-31
Reporting Person: Rose Geoffrey Beran (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-10 | Common Stock | M | 22000 | $1.40 | Acquired | 135861 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-10 | Employee Stock Option (right to buy) | $1.40 | M | 22000 | Disposed | 2025-02-14 | Common Stock (22000) | Direct |
Footnotes
F1: The shares subject to the option are fully vested and immediately exercisable.
More from Pulmonx Corp
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 4
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2025
Dec 11
Director's Dealing
2025
Dec 9
Regulatory Filings
2025
Dec 9
Director's Dealing
2025
Dec 4
Director's Dealing
2025
Dec 4